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Molecular mechanisms by which long noncoding RNA (lncRNA) molecules may influence cancerous condition are
poorly understood. The aberrant expression of SPRIGHTLY lncRNA, encoded within the drosophila gene homolog
Sprouty-4 intron, is correlated with a variety of cancers, including human melanomas. We demonstrate by SHAPE-
seq and dChIRP that SPRIGHTLY RNA secondary structure has a core pseudoknotted domain. This lncRNA interacts
with the intronic regions of six pre-mRNAs: SOX5, SMYD3, SND1, MEOX2, DCTN6, and RASAL2, all of which have
cancer-related functions. Hemizygous knockout of SPRIGHTLY by CRISPR (clustered regularly interspaced short palin-
dromic repeats)/Cas9 in melanoma cells significantly decreases SPRIGHTLY lncRNA levels, simultaneously decreases
the levels of its interacting pre-mRNA molecules, and decreases anchorage-independent growth rate of cells and the
rate of in vivo tumor growth in mouse xenografts. These results provide the first demonstration of an lncRNA’s three-
dimensional coordinating role in facilitating cancer-related gene expression in human melanomas.d f
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 INTRODUCTION
Protein-coding genes constitute only 1.5 to 2% of our genome, and yet,
~75% of the human genome is transcribed; thus, most transcripts are
noncoding RNAs (ncRNAs) (1). Small ncRNAs are now recognized
participants in cancer initiation and progression (2, 3). In recent years,
long ncRNAs (lncRNAs) have emerged as three-dimensional spatial
regulatory molecules, coordinating the expression of multiple genes at
distant or unlinked genomic domains (4–7). There are approximately
58,648 lncRNAgenes (8). The biological functions ofmost lncRNAs are
unknown; a few of these appear to regulate various cellular processes,
including chromatin organization, transcription, and RNA processing
(9–11). Emerging techniques for identifying protein-associated RNA
and DNA molecules by direct sequencing are playing important roles
in dissecting lncRNA function. For example, the lncRNAXIST interacts
with asmany as 81 diverse proteins involved in chromatinmodification,
the nuclearmatrix, and RNA remodeling complexes (12). The existence
of this spatial organizing machinery was repeatedly considered in the
past, but direct evidence has been lacking until recently.
The expression of the lncRNA SPRIGHTLY (formerly known as
SPRY4-IT1) is up-regulated in a variety of cancers (13–19), including
melanoma and prostate cancer. SPRIGHTLY knockdown inmelanoma
and prostate cancer cell lines inhibited cellular proliferation and inva-
siveness and increased apoptosis (20, 21).
Here, we report the comprehensive mapping of SPRIGHTLY
secondary structure by 2′-hydroxyl acylation analyzed by primer
extension sequencing (SHAPE-seq) and identification of domain-
specific SPRIGHTLY-RNA interactions using domain-specific chroma-
tin isolation by RNA purification (dChIRP) analysis. We demonstrate
that SPRIGHTLY interacts with the intronic regions of unprocessed
mRNA precursors of several target mRNAs. Specifically, all three
SPRIGHTLY domains interact with the intronic regions of SMYD3,SND1,MEOX2, SOX5,RASAL2, andDCTN6pre-mRNAs.TheseRNAs
are also physically associated with their respective genomic locations
and, as expected, exhibit differential expression in melanoma cells.
We propose that SPRIGHTLY coordinates the posttranscriptional reg-
ulation of a set of genes by acting as an intranuclear organizing hub, a
general molecular mechanism by which a class of lncRNAs functions.RESULTS
We adapted the method for dChIRP (5, 22) to identify SPRIGHTLY
lncRNA-associated RNAmolecules. dChIRP presents higher sensitiv-
ity and specificity compared to other methods for identifying RNA-
associatedmacromolecules (6, 23, 24).We reasoned that identification
of RNA molecules specifically associating with SPRIGHTLY lncRNA
by dChIRP, which is adapted to the identification of associated RNA
molecules rather than chromatins, will provide comparable resolution.
To design probes complementary to selected regions of SPRIGHTLY
RNA,we experimentally determined itsmost probable secondary struc-
ture (Fig. 1A) by SHAPE-seq and modeling of the resultant sequence
fragments (25). The sugar backbone of the first approximately 120 nu-
cleotides (nt) of SPRIGHTLY are moderately reactive, the next 500 nt
are highly reactive, whereas the remainder of the molecule is relatively
less reactive (Fig. 1B). The secondary structure model exhibits a central
pseudoknotted domain and three other flexible finger-like domains
with intrastrand bulges and loops. Using this structure as a guide, we
were able to design a set of probes to pull down SPRIGHTLY lncRNA
and its interacting partners, as described below.
To identify SPRIGHTLY-interacting RNA partners, we performed a
modified dChIRP assay (fig. S1A and table S1) (5) by hybridizing twelve
biotinylated probes (P1 to P12) (Fig. 1A) to formaldehyde–cross-linked
cellular RNA, followed by streptavidin pulldown, successive elimination
of the associated chromatin proteins and DNA by proteinase and de-
oxyribonuclease (DNase) treatments, respectively, reverse transcription
of theRNA, and sequencingof the resultantmolecules.The region spanned
by P1 to P4was arbitrarily labeledD1, the region spanned by P5 to P8was
labeledD2, and the region spanned by P9 to P12was labeledD3 (fig. S1A).
The pulldown efficiency of each SPRIGHTLY region was determined by
reverse transcriptase–mediated quantitative polymerase chain reaction1 of 8
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 Fig. 1. SPRIGHTLY RNA secondary structure and its binding partners. (A) The secondary structure of SPRIGHTLY was determined by RNA structure with the constraints
of SHAPE-seq reactivity data. Nucleotides are colored by their normalized reactivities r. The probe sequences are labeled P1 to P12. In the text, the 12 primers are
termed in three sets: Set D1 is represented by probes P1 to P4, D2 is represented by probes P5 to P8, and D3 is represented by probes P9 to P12. The core pseudoknotted
domain overlaps D1, D2, and D3. (B) Histogram of normalized SHAPE-seq reactivities as a function of nucleotide position of SPRIGHTLY. (C) The distribution of RNA sequences
within gene bodies corresponding to dChIRP MACS peaks pulled down by the three sets of SPRIGHTLY probes, D1, D2, and D3. dChIRP MACS peaks found in the exonic region
including promoter-TSS, exon, 3′UTR, and TTS were plotted. The aggregate plots of RNA dChIRP sequences peaks show the enriched regions distributed across 5000 base pairs
(bp) upstream of gene bodies and 5000 bp downstream of the genes. The shades represent the SEM. Green peaks represent RNA pulled down by probes of D1, orange peaks
represent RNA pulled down by probes of D2, and purple peaks represent RNA pulled down by probes of D3. (D) SPRIGHTLY binding partner RNAs determined by common
MACS peaks. The MACS peaks were mapped to their corresponding genomic loci, and the number of genes was counted. If MACS peaks from individual dChIRP sequencing
overlapped or mapped to same gene, then those genes were regarded as SPRIGHTLY binding partners. Six genes have MACS peaks common to all three regions, suggesting
that those six genes are most likely to interact with SPRIGHTLY. (E) SPRIGHTLY dChIRP specifically enriches the intronic regions of six genes. SPRIGHTLY dChIRP samples were
analyzed by qPCR using primers for representative MACS peak of each gene or using primers for exon-exon junctions. Each intronic region corresponding to MACS peak was
enriched >5- to 800-fold over the abundant glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. An average of three technical replicates ± SD is shown. (F) The
integrated network of six RNA molecules that bind to SPRIGHTLY was constructed by querying integrated gene interaction network data. Green interaction edges represent
high-confidence genetic interaction data from Lin et al. (51), and black dashed edges represent consensus miRNA target sequences (52).Lee et al., Sci. Adv. 2017;3 : e1602505 3 May 2017 2 of 8
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 (qPCR) using domain-specific primers (table S1). LacZ antisense oligo-
nucleotides were used as negative controls, and background pulldown
of nonspecific materials was negligible (fig. S1A). A total of 3483 se-
quence peaks (normalized against the inputmaterial) were pulled down
[false discovery rate (FDR), <0.05] andweremapped to thegenome (ver-
sionHg19). Of these, 155RNA sequenceswere enriched byD1 probes (P1
to P4), 2896were enriched byD2 (P5 to P8), and 432were enriched byD3
probes (P9 to P12). One hundred eighteen RNA peaks were common be-
tween D1 and D2, 41 were common between D1 and D3, 232 were com-
mon between D2 and D3, and 36 were common to all three domains. The
RNA peak identities, determined by model-based analysis of captured se-
quences (MACS), are listed in table S2. To confirm domain specificities of
the MACS peaks, we performed qPCR with MACS peak–specific primers
using the dChIRPmaterials. As expected, eachMACS peakwas enriched in
a domain-specific manner (fig. S1, B and C). For example, MACS peak
number 14 pulled down by D1 probes P1 to P4 was mainly enriched in
D1 pulldown RNA peaks, but not in D2 or D3 pulldown RNA peaks.
We mapped the RNA MACS peaks to their respective genomic
functional regions: promoter-TSS (transcription start site), exon, intron,
TTS (transcription termination site), 3′UTR (3′ untranslated region),
and intergenic regions (fig. S1D). The majority (52 to 68%) of RNA
MACS peaks corresponded to the intronic regions of coding genes. Less
frequently (21 to 30%), they were spread across multiple loci
corresponding to intergenic regions—a result reminiscent of previous
observations with U1 and MALAT1 lncRNA-interacting chromatin
peaks (7). The enriched RNA MACS peaks were distributed across
the coding and ncRNA regions of various repeat elements [short inter-
spersed nuclear element (SINE), long interspersed nuclear element
(LINE), long terminal repeat (LTR), transposable element (TE), simple
repeats, and satellite sequences] (fig. S2). There were significantly fewer
SINE element-encoded RNA sequences associated with the D3 region
than with the other two regions of SPRIGHTLY. However, the highest
mean fold enrichment of associated RNA was observed with the D3
region, followed by the D1 and D2 regions (fig. S1E). D1 shows high
affinity to both TSSs (present in pre-mRNAs) and TTSs, whereas D2
and D3 mainly interact with RNA sequences embedded within gene
bodies (Fig. 1C). For D2, the mean overall fold enrichment of RNA se-
quences corresponding to exons was statistically significantly higher
than those for intronic or intergenic RNA sequences (fig. S3).
We next identified SPRIGHTLY-interacting RNA partners and
found that D1 interacted with RNA sequences corresponding to 110
coding genes, D2 with 1675 genes, and D3 with 298 genes (Fig. 1D).
RNAs belonging to six genes (SOX5, SMYD3, SND1,MEOX2,DCTN6,
and RASAL2) interacted with all three regions (table S3). The pulldown
sequences of these six genes’ encoded RNAmolecules corresponded to
the intronic regions of their corresponding pre-mRNAs, and the recov-
ered sequences were distributed across the introns of their pre-mRNAs
(table S3). dChIRP was repeated, and all six SPRIGHTLY-interacting
partner pre-mRNAs were validated by qPCR analysis (Fig. 1E) using
two primer sets corresponding to the introns and the two spanning
exons of thesemRNAs, to distinguish between pre-mRNAs and spliced
mRNAs corresponding to their respective MACS peaks.
LncRNAs are thought to coordinate the spatial organization of chro-
matins such that genes that map to distant regions are coordinately
transcriptionally regulated (9).We sought to investigate a variant of this
hypothesis: Pre-mRNAmolecules encoded by genetically unlinked but
functionally related genes are tethered by SPRIGHTLY. To test this hy-
pothesis, we examined whether the mRNAs enriched in the dChIRP
material were functionally related. Gene sets with common functionLee et al., Sci. Adv. 2017;3 : e1602505 3 May 2017ought to be enriched in common gene ontology (GO) annotations,
and these gene groups should be enriched for known genetic or physical
interactions of their respective protein products because these interac-
tions embody functional relatedness. Consistent with this hypothesis,
115 protein-coding genes corresponding to mRNAs pulled down by
the D1-D2, D1-D3, and D2-D3 region pairs (Fig. 1D), and all three
regions combined,were enriched for protein phosphorylation andneuron-
related GO functional terms (table S4). There was significant (FDR-
corrected,P= 6.64 × 10−3) functional enrichment for cellmotility function,
represented by the following genes: FYN, EPHA3, PFN2, STK10,
HSP90AA1, MEF2C, RBFOX2, PDE4D, RERE, CDC42BPA, CDH2,
GPC6, and PDE4B. Of these, RBFOX2 and RERE are important for glial
cell–guided neuron migration in the hindbrain (26, 27). We examined
the four GO-enriched D2-D3 gene subsets (table S5) by querying data-
bases of physical (protein-protein) and genetic interaction networks.
The known genetic or physical interactions within these gene groups,
separately queried according to their GO annotation categories, are
shown in fig. S4 (A to D). Functional analysis of the D2 and D3 region
gene subnetworks (with at least seven genes in the respective sets) re-
vealed significant enrichment for the microtubule-organizing center, pro-
tein phosphorylation, cell migration, and regulation of neuron projection
development functions (table S5). When the genes corresponding to the
set of 74 mRNAs pulled down by D2 and D3 regions were queried
together, they constituted a 60-member interaction network densely in-
terconnected by numerous known genetic interaction edges (fig. S4E),
suggesting a high degree of functional overlap. In addition to the genes
enriched by D2-D3 pulldown, we examined the genes corresponding to
the set of six mRNAs pulled down by all three domains. This six-gene
subset constituted a connectednetworkof genes related by knowngenetic
interactions and as putative co-regulated targets of two microRNAs
(miRNAs) that were previously identified as important for cancers of
the lungs, breast, liver, and pancreas (Fig. 1F).
To investigate the dependence of expression levels of the six binding
partners on SPRIGHTLY, we knockedout SPRIGHTLYbyusingCRISPR
(clustered regularly interspaced short palindromic repeats)/Cas9. Two
guide RNAs targeting the upstream and downstream regions of
SPRIGHTLY (fig. S5A) were introduced to cells stably expressing Cas9p.
Single-cell clones were isolated, and PCR analysis of genomic DNAdem-
onstrated that one allele had the appropriate deletion to produce hemi-
zygous SPRIGHTLY knockout in the SC2-17 cells (fig. S5B). SPRIGHTLY
expression levels in SC2-17 cells decreased by approximately 80% com-
pared to those of the parental cells (fig. S5C).
To confirm that SPRIGHTLY lncRNA colocalizes with its target
pre-mRNA molecules, we applied dual RNA-FISH (fluorescence in
situ hybridization) assays on A375 and SC2-17 cells (Fig. 2, A to F).
We designed single-molecule FISH (smFISH) probes specific for
SPRIGHTLY and found that SPRIGHTLY lncRNA is primarily loca-
lized in the cell nucleus (Fig. 2B). We did not detect RNA-FISH signals
for SPRIGHTLY in SC2-17 cells, suggesting that hemizygous deletion of
SPRIGHTLY causes a sharp decrease in SPRIGHTLY RNA expression
(Fig. 2, B and F). Statistically significant colocalization of SPRIGHTLY
lncRNA and its partner pre-mRNAs encoded by SMYD3 and SND1
(Fig. 2, D, E, and G) confirms the genome-wide dChIRP data on these
twoRNAs (Fig. 1E) and also reinforces the idea that physical association
between SPRIGHTLY and these two pre-mRNAmolecules is function-
ally relevant. To investigate the effects of this physical association on
mRNA expression levels, we next measured the expression levels of the
six SPRIGHTLY binding partner RNAs by qPCR. As shown in Fig. 2H,
both mRNA and pre-mRNA levels of SMYD3, SOX5, and RASAL2were3 of 8
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 significantly decreased in SC2-17 cells relative to those in A375 cells.
Whereas pre-mRNA levels were decreased, no changes were observed
in the mature mRNA levels of SND1 andMEOX2 genes.
To investigate the role of SPRIGHTLY in cancer development, we
monitored anchorage-independent growth of hemizygous SPRIGHTLY
knockout SC2-17 cells and compared them with those of their parental
A375 cells. Cells were cultured in a semisolid culture medium, and
their colony-forming ability was measured (Fig. 2I) by the MTT
[3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide]
assay. There was a significant reduction in colony formation ability of
SPRIGHTLY knockout cells compared to that of parental cells, and the
reductionwas reversed by complementationwith the SPRIGHTLY gene
under a constitutive promoter (fig. S6A). The ectopic expression of
SPRIGHTLY in SC2-17 cells recovered the expression levels of its
RNA binding partners (fig. S6B). We next determined the profile of
SPRIGHTLY-dependent gene expression by RNA sequencing
(RNA-seq) conducted on parental A375 and hemizygous SPRIGHTLYLee et al., Sci. Adv. 2017;3 : e1602505 3 May 2017knockout SC2-17 cells. In the knockout line, 117 genes were significant-
ly down-regulated (−1.3 ≥ log2 (ratio) ≥ −9.4; 4.2 × 10
−16 ≤ FDR-
corrected P ≤ 0.05). This down-regulated gene set overlapped with
genes (28) in the cancer modules #112 (FDR-corrected, P = 9.9 × 10−8)
and #55 (FDR-corrected, P = 1.11 × 10−3), respectively, with genes in the
cell signaling module #176 (FDR-corrected, P = 5.98 × 10−8), with genes
in the neural development gene modules #2 (FDR-corrected, P = 2.9 ×
10−5) and #12 (FDR-corrected, P = 2.24 × 10−5), respectively, and with
the genes in immune and inflammatory response module #84 (FDR-
corrected, P = 4.65 × 10−5). Finally, we investigated SPRIGHTLY’s
in vivo biological role in xenografts on severe combined immuno-
deficient (SCID) mice. Whereas control A375 cells were readily able
to form subcutaneous tumors in SCIDmice, SC2-17 cells exhibited sig-
nificantly reduced tumorigenicity. The tumor volume differences
became apparent by day 20 (Fig. 2J) and were confirmed by measuring
the tumor weight and size after sacrificing the mice at day 31 (Fig. 2,
K and L).Fig. 2. SPRIGHTLY hemizygous knockout suppresses anchorage-independent growth in vitro and the tumor growth in vivo. (A to G) Colocalization between
SPRIGHTLY and intronic regions of SMYD3 and SND1: (A) the differential interference contrast (DIC) image of parental and knockout cells, (B) raw image showing SPRIGHTLY RNA
probed using smFISH probes labeled with Texas Red, (C) raw images showing SND1 RNA (top two panels), and SMYD3 RNA (bottom two panels) probed using probes labeled with
tetramethylrhodamine (TMR). (D)Merge of RNA spots for SPRIGHTLY are pseudocolored as green, and SND1 and SMYD3 are pseudocolored as red. (E) The spotswere identified using
custom-written algorithms in MATLAB. WT, wild type; KD, knockdown. The identified spots are overlaid over 4′,6-diamidino-2-phenylindole (DAPI) staining as red (SND1/SMYD3),
green (SPRIGHTLY), and yellow (colocalized) circles. (F)Quantification of about 50 cells to determine the copynumber. (G) Extent of colocalization of SND1 and SMYD3with SPRIGHTLY
lncRNA. The error bars represent 95% confidence interval. Scale bars, 5 mm. (H) SPRIGHTLY hemizygous knockout decreased the expression levels of both mRNA and pre-mRNA of
RNA binding partners. The expression levels were measured in both A375 and SC2-17 cells by qPCR. The expression levels of both mRNA and pre-mRNA of TBP or HPRT1were not
affectedby SPRIGHTLY in SC2-17 cells. Delta threshold cycle (DCt)was calculatedby subtracting the averageCt valueofACTB, TBP, andHPRT1 fromtheCt valueof target gene. Thedata
were obtained from three independent experiments and are expressed as means ± SD. ns, not significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, Student’s t test. (I) A375
and SC2-17 cells were seeded and cultured for 7 days. Shown is a representative image of impaired colony-forming ability in SC2-17 cells compared to control cells (A375). The MTT
assay was used to determine cell number. Results are expressed asmeans ± SD from six independent experiments. ****P≤ 0.0001, Student’s t test. (J to L) Five-week-old female SCID
micewere subcutaneously injectedwith either A375 or SC2-17 cells (n=4mice per group). (J) Graph depicts tumor volume (volume= (width)2 × length/2) observed for theA375 and
SC2-17 groups at different time points until the tumors were excised. (K) Approximately 1 month after implantation, mice were euthanized, and tumors were excised and weighed.
Graph depicts tumorweight (inmilligrams) of A375 and SC2-17 tumor xenografts. (L) Images of the excised tumors on a scale bar are shown. Student’s t test was performed to detect
between-group differences. The data in (J) and (K) are representative of at least three independent experiments with consistent results. **P ≤ 0.01, Student’s t test.4 of 8
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 DISCUSSION
By adapting ncRNA-associated chromatin precipitation and identifica-
tion technique to identifying SPRIGHTLY-interacting RNAmolecules,
we discovered that this lncRNA interacted with more than 2000 differ-
ent high-confidence RNAmolecules. To do this, we analyzed the topo-
logical shape of SPRIGHTLY, and guided by its structure, we designed
three sets of probes that interrogated three overlapping structural do-
mains,D1,D2, andD3, including a predicted pseudoknotted core struc-
ture. Not all the ~2000 high-confidence binding partners may be
authentic; however, those RNAs that bind to two domains each, and
especially the six RNA molecules (SOX5, SMYD3, SND1, MEOX2,
DCTN6, and RASAL2) that are bound to all three domains, represent
high-confidence interaction partners of SPRIGHTLY. On the basis of
the distribution and topological overlaps of the three sets of probes
complementary to the three structural domains of SPRIGHTLY, we infer
that these six highest-confidence interacting RNAmolecules are likely to
interact with structural features that are common to all three regions—
namely, the pseudoknotted central core minimally overlapping P2 (of
D1), P7 (of D2), and P11 (of D3). Future in vitro cross-linking experi-
ments with purified SPRIGHTLY and the pre-mRNAs transcribed off
these genes will be necessary to test this prediction.
Our observations that SPRIGHTLY was more frequently associated
with RNA sequences corresponding to the intronic regions of protein-
coding RNAs and less frequently with RNAs expressed from intergenic
regions are consistent with previous observations withU1 andMALAT1
lncRNA-interacting chromatin peaks (7). The chromatin regions cor-
responding to introns of protein-coding genes are more frequently asso-
ciated with these two lncRNAs relative to intergenic regions. If this
correspondence between RNA- and chromatin-interacting partners
holds also for SPRIGHTLY chromatin binding (not investigated here),
then these results would imply that lncRNAs are intimately associated
with selected chromatin regions in large supramolecular assemblies that
include both chromatin and nascent pre-mRNAs transcribed off those
chromatin regions. RNA sequences corresponding to promoter-TSS re-
gions, exons, TTS, and 3′UTRs were relatively infrequently associated
with the three structural domains of SPRIGHTLY compared to the intro-
nic and intergenic ncRNA regions. Although the numbers of RNA
MACSpeak enrichmentwere different for all three domains, the normal-
ized intronic enrichment percentages were similar.
The six genes that encode the highest-confidence pre-mRNA
binding partners of SPRIGHTLY were previously identified to play im-
portant roles in cancer. The transcription factor SOX5 negatively reg-
ulates microphthalmia-associated transcription factor, whose level is
low in invasivemelanoma cells, by competingwith SOX10 for promoter
binding sites in normal melanocytes (29). SMYD3 encodes histone H3-
K4 di-/trimethyltransferase and H4-K5-methyltransferase activities,
causes transcriptional activation, and regulates the expression of critical
cancer-associated proteins, such as the androgen receptor, c-Met, telo-
merase reverse transcriptase, and matrix metalloproteinase 9 (30, 31).
SMYD3 overexpression is associated with brain tumors and colorectal,
hepatocellular, breast, and prostate cancers (32–35). SND1 encodes a
Tudor domain nuclease, whose expression is associated with metastatic
melanoma, andwas initially identified as a transcriptional coactivator of
PIM1-mediated control of C-MYB expression and later as a component
of the RNA-induced silencing complex (36). SND1 modulates tran-
scriptional activation, RNA splicing, RNA editing, RNA stability, and
RNAi function; promotes invasion, proliferation, migration, and angi-
ogenesis in liver cancer; and promotes invasion andmetastasis in breast
cancer (37). SND1 knockdown reduces prostate cancer cell line prolif-Lee et al., Sci. Adv. 2017;3 : e1602505 3 May 2017eration rate (38), and its high expression is associated with colorectal
cancer and malignant glioma (39, 40). The finding that these six pre-
mRNA molecules are associated with SPRIGHTLY at the highest con-
fidence level suggests that SPRIGHTLY predominantly interacts with
these six pre-mRNA molecules, presumably through SPRIGHTLY’s
pseudoknotted central core, and that the interaction targets the introns
of unspliced RNAmolecules. Results of statistical analysis of function-
al enrichment of gene sets associated with SPRIGHTLY are also
consistent with the hypothesis that SPRIGHTLY lncRNA binds to
many more functionally related pre-mRNA molecules than just the
six highest-confidence pre-mRNAs, which, at the very least, are en-
coded by genes important for cellmotility,migration, neuronalmigra-
tion, and cancers in general.
We have tested the hypothesis that the transcript levels from selected
target genes might be controlled by SPRIGHTLY, by analyzing the
coordinate expression of pre-mRNA and mature mRNA from the six
genes in cells harboring a hemizygous knockout of SPRIGHTLY. The
knockout event is associated with ~80% reduction in SPRIGHTLY
RNA levels. The results indicate that SMYD3, SOX5, and RASAL2
mRNA levels are directly regulated through a common mechanism
involving SPRIGHTLY, which is also supported by the existence of
genetic interaction among these four genes (Fig. 1F). The influence of
SPRIGHTLY on the other two mRNAs might be indirect and more
complex, because their pre-mRNA levels but not their mature mRNA
levels were perturbed in the hemizygous knockout cells.
RNA-seq analysis in cell lines with or without the hemizygous
knockout demonstrated that RNA levels of gene sets with provocative
functions in melanoma and brain metastasis are significantly reduced
when SPRIGHTLY expression is reduced. This is exactly the result an-
ticipated if SPRIGHTLY lncRNA increases the expression of tumor-
and metastasis-related genes, including those potentially important
for metastasis into neural tissues. As expected, mouse xenograft studies
with unmodified and SPRIGHTLY knockout melanoma cell lines con-
firmed that tumor growth rateswere directly correlatedwith SPRIGHTLY
expression levels.
In conclusion, we have provided evidence demonstrating that
SPRIGHTLY lncRNA acts as a posttranscriptional nuclear hub by bind-
ing to the intronic regions of a set of pre-mRNA molecules that are
enriched for cancer-related functions, especially those related to cell
motility as well as cell migration into the brain, and thereby regulates
the latter’s biological functions. This has significant implications, be-
causemore than 60% of deaths from invasivemelanoma are due tome-
tastasis to the brain (41).MATERIALS AND METHODS
Tissue culture
A375 cells (American Type Culture Collection, CRL-1619) were grown
in Complete Tu Medium containing a 4:1 mixture of MCDB-153 me-
dium with sodium bicarbonate (1.5 g/liter) and Leibovitz’s L-15 medi-
umwith 2mML-glutamine, 2% fetal bovine serum, and 1.68mMCaCl2
(42). The cells were grown in a humidified incubator at 37°C, 5% CO2.
dChIRP oligonucleotide design
Biotinylated 20-mer antisense oligonucleotides were designed using the
Stellaris smFISH probe designer (http://biosearch.com/) (6). Designed
probes were compared with the human genome using the BLAT tool,
andprobes returningonly targetwere selected (table S1). ForLacZprobes,
six biotinylated 20-mer antisense oligonucleotides were prepared (5).5 of 8
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 Modified dChIRP
dChIRP was performed as previously described (5). Cells were cross-
linked with 0.3% formaldehyde for 10min, quenched with 0.125M gly-
cine for 5 min, and washed with phosphate-buffered saline. Sheared
chromatinwas prepared by sonication using a Bioruptor 300 (Diagenode)
to produce DNA between 100 and 500 bp. Chromatin was diluted three
times with hybridization buffer, and probes were added (15 pmol per
chromatin from 1 million cells). The mixture was incubated overnight
at 37°C with rotation. Streptavidin magnetic C1 beads (Thermo Fisher
Scientific Inc.) were added and mixed for another 2 hours at 37°C. After
extensivewashing, the beadswere resuspended in a buffer containing pro-
teinase K (Sigma-Aldrich) and incubated at 50°C for 45 min, followed by
overnight incubation at 65°C for reverse cross-linking. RNAs were
extracted by TRIzol/chloroform and precipitated with ethanol. The puri-
fied RNAs were treated with DNA-free reagent (Life Technologies) to
eliminate DNA according to the manufacturer’s protocol. DNase was in-
activated by heating at 65°C for 15min, andRNAswere quantified using a
Qubit 2.0 Fluorometer (Thermo Fisher Scientific Inc.).
Sequencing and data analysis
dChIRPed RNAs were subjected to double-stranded complementary
DNA synthesis using an Ovation RNA-Seq System V2 (NuGEN Tech-
nologies Inc.). High-throughput sequencing libraries were constructed
using the TruSeq ChIP Sample Preparation Kit (Illumina) and se-
quenced on a HiSeq 2500 (Illumina) with 50-bp read lengths. Sequen-
cing data were analyzed as previously described (6). dChIRP peaks were
defined byMACS (43) as previously described (5). The peakswere iden-
tified by MACS2 program software, and the q value (≤0.05) was as-
signed as the cutoff by Benjamini-Hochberg correction.
2′-hydroxyl acylation analyzed by primer extension
sequencing (SHAPE-Seq)
SPRIGHTLY RNA was prepared by in vitro transcription using the
MEGAscript kit (Life Technologies) with PCR product DNA as tem-
plate. RNAwas purified using the Direct-zol RNAMiniPrep kit (Zymo
Research). Purified RNA was heated at 95°C for 2 min, snap-cooled on
ice, and refolded in a buffer containing 100 mMHepes-KOH (pH 8.0),
100 mM NaCl, and 10 mM MgCl2 for 20 min at 37°C. The refolded
RNAswere treated with 6.5mMN-methylisatoic anhydride (Life Tech-
nologies) at 37°C for 50min. RNAswere recovered using RNAClean&
Concentrator-25 (ZymoResearch). For sequencing, themodifiedRNAs
were subjected to library construction, as previously described (25), with
slight modification. Universal miRNA Cloning Linker (New England
Biolabs) was used as an RNA linker, and all ethanol precipitation
steps were replaced with column purification using RNA Clean &
Concentrator-25 (Zymo Research). Libraries were used for nine-cycle
PCR amplification with primers containing Illumina sequencing and
indexmultiplexing and then sequenced on the IlluminaHiSeqplatform.
Adapters and primers were listed in table S1.
SHAPE-seq data analysis
Channel reads [1,041,097 (+) and 601,817 (−)]were collected fromSHAPE-
seqexperiments.Reverse transcriptaseprimerswere trimmed fromthereads
usingCutadapt version1.10 (44).Handle sequenceswere kept for separating
(+) and (−) channel reads. Both (+) and (−) channel reads were combined
into one file and thenmapped to SPRIGHTLY by Bowtie version 1.0.0 (45).
Spats version 1.0.0 (46) was performed to calculate the reactivity value for
each nucleotide in SPRIGHTLY from the mapping result. The reactivity
values q were normalized to SHAPE-seq reactivities r by multiplyingLee et al., Sci. Adv. 2017;3 : e1602505 3 May 2017the length of the transcript. RNAstructure version 5.8.1 was performed
to predict the secondary structure with the SHAPE-seq reactivity data.
The parametersm and bwere set to 1.1 and−0.3, respectively, following
the guide of the SHAPE-seq 2.0 protocol (25). VARNA version 3.93
(47) was used to visualize the predicted secondary structure.
Single-molecule fluorescence in situ hybridization
A set of probes, each 20 nt long, was designed specifically to the intron
10 and 15 of SND1 (32 probes) and intron 5 of SMYD3 (48 probes). The
region of probe binding was selected to overlap theMACS peak regions
identified in theChIRP analysiswhile avoiding any repetitive sequences.
Another set of 25 probes was designed to bind SPRIGHTLY lncRNA.
The probes were ordered from LGC Biosearch LLC with a 3′-amino
modification and were coupled with either tetramethylrhodamine for
the intronicprobesorTexasRed for theSPRIGHTLYprobes.TheA375cells
(both wild type and the cell line with SPRIGHTLY knockout) were
cultured on glass coverslips, fixed, permeabilized, and hybridized with
lncRNAprobeandoneof the intronprobe sets.Thenextday, theunbound
probes were washed off, and the coverslips were mounted and imaged
using a Nikon Ti-E inverted wide-field fluorescence microscope with a
100× objective and a cooled charge-coupled device pixis camera.
Image acquisition and analysis
The images were acquired using MetaMorph imaging software. We
acquired approximately 30 optical slices at 0.2-mm intervals, thereby
covering the entire volume of the cells. The images were analyzed
to determine the numbers and colocalization between lncRNA and
introns using custom-written algorithms in MATLAB (MathWorks
Inc.), as described before (48). Briefly, the program analyzed the
whole z stacks and removed nonuniform background to enhance
particulate signal. The RNA spots in each channel were then identified
in a semiautomated way by picking an intensity threshold. The signal
below the threshold was discarded as background, and only the signal
above background was considered as an RNA particle. Then, a custom-
written program was used to determine the colocalization between spots
in different channels, as described before (49). All the colocalization data
were validated by using appropriate controls, as described in literature
(50). The MATLAB program scripts are available upon request.
Soft agar colony formation assays
Anchorage-independent growth assays were performed by seeding
10,000 cells suspended in 0.3% base agar in 96-well plates coated with
0.6% base agar using a CytoSelect 96-well cell transformation assay kit
(Cell Biolabs Inc.). Colonies were counted 7 days after seeding and ana-
lyzed using MTT solution provided with the kit according to the man-
ufacturer’s protocol. The data from six independent experiments were
expressed as means ± SD.
GO and network analysis
GO analysis was peformed using g:Profiler. Subsets of genes that
were enriched in GO function were queried against the physical
protein interaction databases CORUM and BioGRID (Biological
General Repository for Interaction Datasets) and a genetic interac-
tion database to generate gene subnetworks using the GeneMANIA
application from within Cytoscape.
Mouse xenograft study
Five-week-old SCID mice were purchased from Charles River La-
boratories. Three to 5 days of acclimatization after arrival, the inoculation6 of 8
SC I ENCE ADVANCES | R E S EARCH ART I C L Earea was shaved to remove body hair and sterilized with ethanol. A375
or SC2-17 cells (5.0 × 106 cells per site; n = 4 mice per group) were
subcutaneously injected into the lower left flank of each mouse with a
27-gauge needle. Tumor size was monitored daily with digital calipers
and documented once tumor growth became visible (after day 4). Tu-
mor volume (in cubic millimeters) was calculated by the following
formula: volume = (width)2 × length/2. Mice were euthanized on day
31 after injection, and weight and pictures of excised tumors were taken.htt
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